Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
Burlington, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1488% % 56%
Debt-to-equity 7.2% % -38%
Return On Equity -83% % 33%
Return On Assets -77% % 31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,795,260 shares -27%
Common Stock, Shares, Outstanding 1,795,260 shares -14%
Entity Public Float $1,565,909 USD -62%
Common Stock, Value, Issued $1,795 USD -14%
Weighted Average Number of Shares Outstanding, Basic 1,795,097 shares 514%
Weighted Average Number of Shares Outstanding, Diluted 1,795,097 shares 514%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,907,563 USD 30%
General and Administrative Expense $2,149,211 USD -8.6%
Operating Income (Loss) $4,056,774 USD -6.1%
Nonoperating Income (Expense) $110,711 USD 384%
Net Income (Loss) Attributable to Parent $3,946,063 USD 4.7%
Earnings Per Share, Basic 12 USD/shares 7.9%
Earnings Per Share, Diluted 12 USD/shares 7.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $6,350,799 USD 56%
Assets $6,350,799 USD 56%
Liabilities, Current $334,282 USD 22%
Liabilities $334,282 USD 22%
Retained Earnings (Accumulated Deficit) $87,445,726 USD -4.7%
Stockholders' Equity Attributable to Parent $6,016,517 USD 59%
Liabilities and Equity $6,350,799 USD 56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $926,125 USD 29%
Net Cash Provided by (Used in) Financing Activities $347,549 USD -77%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 1,795,260 shares -14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $578,576 USD -388%
Deferred Tax Assets, Valuation Allowance $21,682,000 USD 6.2%
Deferred Tax Assets, Gross $21,682,000 USD 6.2%
Deferred Tax Assets, Operating Loss Carryforwards $10,771,000 USD 12%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Additional Paid in Capital $93,460,448 USD 7.1%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%